Tag Archives: Prof Olav Mella

B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results

Posted on April 3, 2019 by wames

B-lymphocyte depletion in patients With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: a randomized, double-blind, placebo-controlled trial by Oystein Fluge, Ingrid G. Rekeland, Katarina Lien, Hanne Thurmer, Petter C. Borchgrevink, Christoph Schafer, Kari Sorland, Jorg Assmus, Irini Ktoridou-Valen, Ingrid Herder, Merethe E. … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results

Immunosignature analysis of ME/CFS – promising diagnostic biomarker

Posted on October 15, 2018 by wames

Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Oliver P Günther, Jennifer L Gardy, Phillip Stafford, Øystein Fluge, Olav Mella, Patrick Tang, Ruth R Miller, Shoshana M Parker, Stephen A Johnston, David M Patrick in Molecular Neurobiology (2018) pp 1-9 [Published online: … Continue reading →

Posted in News | Tagged , , , , , , , , , , , , , | Comments Off on Immunosignature analysis of ME/CFS – promising diagnostic biomarker

Norwegian rituximab trial reports negative results

Posted on November 28, 2017 by wames

The Norwegian Rituximab trial reports negative results ahead of the publication of the full results. Attempts are now under way to determine the best way forward in understanding what has been learned and how to find out which patients may still benefit from … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Norwegian rituximab trial reports negative results

Norwegian Rituximab studies update

Posted on November 3, 2017 by wames

Helse Bergen blog post, 29 Sep 29017: RituxME B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome (“RituxME”) ​RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on Norwegian Rituximab studies update

Fuel shortage: Norwegian study expands on energy problem in ME/CFS

Posted on January 9, 2017 by wames

Health rising blog post, by Cort Johnson, 27 Dec 2016: Fuel shortage: Norwegian study Expands on Energy Problem in Chronic Fatigue Syndrome (ME/CFS) Fluge and Mella seem to be working at almost lightning speed. Besides managing their huge Rituximab study … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Fuel shortage: Norwegian study expands on energy problem in ME/CFS

Metabolic profiling indicates impaired pyruvate dehydrogenase function in ME/CFS

Posted on December 23, 2016 by wames

Research abstract: Myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is a debilitating disease of unknown etiology, with hallmark symptoms including postexertional malaise and poor recovery. Metabolic dysfunction is a plausible contributing factor. We hypothesized that changes in serum amino acids may disclose … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Metabolic profiling indicates impaired pyruvate dehydrogenase function in ME/CFS

Mella finds hypometabolic state in ME/CFS

Posted on October 17, 2016 by wames

Health rising blog post, by Cort Johnson, 15 October 2016: Another Hypometabolic Signature Found Fluge and Mella are best known for their Rituximab work, but just last week Mella reported that they’d found a hypometabolic state in ME/CFS as well. … Continue reading →

Posted in News | Tagged , , , , , , , , , | Comments Off on Mella finds hypometabolic state in ME/CFS

New rituximab trial results from Norway

Posted on August 22, 2016 by wames

Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on New rituximab trial results from Norway

Cancer doctor Dagfinn Øgreid has treated ME patients with rituximab

Posted on November 26, 2015 by wames

Blog article: Offers private ME treatment with cancer drugs – scientists react, by Anne Grete Storvik, Nov 23 2015 in Dagensmedicin [ translated by Google translate] A private clinic in Sandnes offers treatment for ME with the cancer drug rituximab. Patients pay … Continue reading →

Posted in News | Tagged , , , , , , | 1 Comment

UK rituximab trial fundraising total almost reached

Posted on September 28, 2015 by wames

Invest in ME has announced the latest fundraising total for the rituximab/B-cell research, which is a great boost as the research team at UCL are about to visit and discuss the subject with Dr Fluge and Professor Mella in Haukeland University Hospital, … Continue reading →

Posted in News | Tagged , , , , , , , | Comments Off on UK rituximab trial fundraising total almost reached